AKR vs BMY · P/E 70, rev $410.8M vs P/E 17, rev $24.46B
Acadia Realty Trust (AKR) versus Bristol-Myers Squibb Company (BMY) — a side-by-side from cached financials, not a winner call.
Acadia Realty Trust (AKR) is a reit - retail company listed on US.
Bristol-Myers Squibb Company (BMY) is a drug manufacturers - general company listed on US. It is led by Christopher S. Boerner Ph.D..
Latest reported AKR revenue for 2025-12-31 was $410.8M. Net income was $16.9M. Revenue was up 14.2% from 2024-12-31 to 2025-12-31. AKR currently screens at market cap $3.16B and trailing P/E 70.3.
Latest reported BMY revenue for 2026-06-30 was $24.46B. Net income was $5.99B. BMY currently screens at market cap $95.36B and trailing P/E 17.5.
AKR currently screens at market cap $3.16B and trailing P/E 70.3. BMY currently screens at market cap $95.36B and trailing P/E 17.5.
Not investment advice. Open the AKR and BMY stock pages for the full models.
Not investment advice.